Illumina, Inc. vs Veritone Inc — how do they compare? Illumina, Inc. trades at $278.17 (market cap $39.95B), while Veritone Inc trades at $0.56 (market cap $59.46M). The key difference: Illumina, Inc. is far larger — about 671.9× Veritone Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Veritone Inc for 12 Days on average.
| ILMN | VERI | |
|---|---|---|
Market Cap | $39.95B | $59.46M |
Volume | 3,169,503 | 15,523,164 |
Sector | Health | Technology |
52-Week High | $293.69 | $8.39 |
52-Week Low | $91.00 | $0.59 |
Typical Hold Time | 83 Days | 12 Days |
Enterprise Value | $41.31B | $94.86M |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $278.17, up 3.89% today and near its 52-week high of $278.99. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent inclusion in the S&P 500 and positive analyst upgrades reflect growing institutional confidence. Revenue remains stable at $4.34B for 2025 with improved profitability, delivering $850M net income after previous losses.
The outlook remains positive with sequencing growth and AI initiatives driving momentum, though elevated valuation ratios and China market headwinds present risks. Analyst consensus leans bullish with 54% buy ratings, but the current price exceeds the $241 consensus target, suggesting near-term consolidation potential before further upside.
Veritone (VERI) trades at $0.5647, down 18.31% over 24 hours, reflecting significant bearish pressure. The stock shows mixed signals with a bearish technical outlook but bullish oscillators. Fundamentally, the company reported a net loss of $111.73M in 2025 with a negative net income margin of -117.54%, though revenue remains near $92M. Recent developments include a $15M equity offering and partnerships with ATP Media and ZeroEyes, indicating ongoing business development efforts amidst financial challenges.
The outlook for VERI is highly speculative, with a consensus analyst price target of $3.75 suggesting substantial upside potential from current levels. However, persistent losses, negative cash flow from operations, and ongoing securities litigation pose significant risks. Investment appeal hinges on the company's ability to achieve profitability and monetize its AI solutions, making it suitable only for risk-tolerant investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →